Bruce Belanger

Bruce has more than 25 years of experience in nonclinical and clinical drug development in multiple therapeutic areas including infectious diseases, oncology, neurology, and rare diseases. Bruce has extensive experience leading biometry work in all phases of clinical development and in health authority interactions for multiple drug approvals.

Prior to joining Atea, Bruce most recently served as Senior Director, Biostatistics Due Diligence at Ipsen. Prior to his position at Ipsen, he held clinical development biometrics head of function roles at Merrimack Pharmaceuticals, Tolerx, and Idenix Pharmaceuticals. Bruce began his career at Schering-Plough, supporting nonclinical work, and in positions after Schering-Plough he was a statistical lead on Phase 3 programs at Praecis Pharmaceuticals and Genzyme.

Bruce holds a BA in Mathematics from Boston University and a PhD in Statistics from North Carolina State University.